Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren Shea

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 24, 2015
Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophyJacqueline A Hawkins-Salsbury, Lauren Shea, Xuntian Jiang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 24, 2020
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin LymphomaLauren Shea, Marcus P Watkins, Fei Wan, et al.
Cancer Genetics|March 6, 2026
Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursorsFelicia Gomez, Lauren Shea, Sivasankar Annamalai Sharavanan, et al.
Blood Advances|June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Blood Cancer Journal|March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centersTimothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 24, 2015
Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophyJacqueline A Hawkins-Salsbury, Lauren Shea, Xuntian Jiang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 24, 2020
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin LymphomaLauren Shea, Marcus P Watkins, Fei Wan, et al.
Cancer Genetics|March 6, 2026
Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursorsFelicia Gomez, Lauren Shea, Sivasankar Annamalai Sharavanan, et al.
Blood Advances|June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Blood Cancer Journal|March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centersTimothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 2